spantide

antagonizes both bombesin & substance P; tachykinin receptor antagonist

Also Known As:

1-Arg-7,9-Trp-11-Leu-substance P; spantide I; substance P, Arg(1)-Trp(7,9)-Leu(11)-; substance P,arginyl(1)-tryptophyl(7,9)-leucine(11)-

Networked: 36 relevant articles (3 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Barrett, Ronald P: 2 articles (04/2008 - 02/2007)
2.	Hazlett, Linda D: 2 articles (04/2008 - 02/2007)
3.	McClellan, Sharon A: 2 articles (04/2008 - 02/2007)
4.	Zhang, Yunfan: 2 articles (04/2008 - 02/2007)
5.	Dana, Reza: 1 article (01/2020)
6.	Liu, Lingjia: 1 article (01/2020)
7.	Yin, Jia: 1 article (01/2020)
8.	Channappanavar, Rudragouda: 1 article (11/2011)
9.	Suvas, Susmit: 1 article (11/2011)
10.	Twardy, Brandon S: 1 article (11/2011)

Related Diseases

1.	Corneal Perforation 02/01/2007 - "The SP antagonist Spantide provides a novel approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea of B6 mice, leading to a significant reduction in corneal perforation and improved disease outcome." 04/01/2008 - "Studies have shown that blocking substance P (SP) binding to neurokinin 1 receptor with spantide I prevents Pseudomonas aeruginosa-induced corneal perforation in susceptible C57BL/6 mice. " 02/01/2007 - "Spantide I decreases type I cytokines, enhances IL-10, and reduces corneal perforation in susceptible mice after Pseudomonas aeruginosa infection."
2.	Spinal Injuries (Spinal Injury) 11/15/1988 - "Thyrotropin releasing hormone (TRH), which has been shown to improve neurologic recovery following cervical contusive spinal injury in cats, has also recently been reported to prevent the neuronal damage produced by the intrathecal (i.t.) administration of the substance P antagonist, spantide. "
3.	Corneal Opacity 11/04/2011 - "Subconjunctival inoculation of spantide I during the clinical phase of HSK resulted in significant reduction in the corneal opacity and angiogenesis. "
4.	Miosis 12/17/1991 - "The tachykinin antagonist spantide inhibited the miosis but had no effect on the rise in intraocular pressure. " 01/01/1990 - "Previous observations have indicated that topical application to the rabbit eye of tachykinin antagonists, including spantide, effectively prevents the miosis and the disruption of the blood-aqueous barrier consequent to ocular injury. " 04/01/1997 - "4. The ECT-evoked miosis was also inhibited by pretreatment with the tachykinin receptor antagonist D-Pal9 spantide 11 (90 nmol, intravitreal injection); under these circumstances the maximal reduction in pupil size was only 0.7 +/- 0.03 mm, indicating an important role for SP in the miotic response. "
5.	Contracture 01/01/1987 - "Contracture of the ileum was inhibited by the tachykinin antagonist, spantide, and was therefore presumably mediated by a substance P-like agent. " 12/01/1990 - "The adenosine (5 microM) washout contracture, in common with MEnk and noradrenaline washout contractures, was inhibited by the substance P antagonist, spantide (10 microM). " 06/01/1985 - "The phentolamine-precipitated withdrawal contracture following 2 min contact of ileum with clonidine was abolished by atropine, 5 mumol 1(-1), and substance P (SP) antagonists, (D-Pro2,D-Phe7, D-Trp9)-SP and spantide, 10 mumol 1)-1). "

Related Drugs and Biologics

1.	Substance P
2.	Interleukin-10 (Interleukin 10)
3.	Cytokines
4.	Thyrotropin-Releasing Hormone (Protirelin)
5.	Neurokinin-1 Receptors (Neurokinin 1 Receptor)
6.	Tachykinins
7.	Neurokinin-1 Receptor Antagonists
8.	Peptides (Polypeptides)
9.	Capsaicin (Zostrix)
10.	Benzoic Acid (Potassium Benzoate)

Related Therapies and Procedures

1.	Slit Lamp
2.	Intravitreal Injections
3.	Intradermal Injections
4.	Aftercare (After-Treatment)